Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

MYOSITIS

Amyloid-PET: a new tool for diagnosing IBM?

Nature Reviews Rheumatology volume 15, pages 321–322 (2019)Cite this article

Subjects

Inclusion body myositis (IBM) and polymyositis can normally be distinguished on the basis of clinical features. However, patients with an atypical disease presentation, particularly those with early-stage disease, can be challenging to diagnose. Can imaging with amyloid-PET help distinguish these two diseases?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Greenberg, S. A. Inclusion body myositis: clinical features and pathogenesis. Nat. Rev. Rheumatol. https://doi.org/10.1038/s41584-019-0186-x (2019).

    Article  PubMed  Google Scholar 

  2. Lilleker, J. B. et al. [18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. Ann. Rheum. Dis. 78, 657–662 (2019).

    Article  Google Scholar 

  3. Chahin, N. & Engel, A. G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70, 418–424 (2008).

    Article  Google Scholar 

  4. Pruitt, J. N. 2nd, Showalter, C. J. & Engel, A. G. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann. Neurol. 39, 139–143 (1996).

    Article  Google Scholar 

  5. Wong, D. F. et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med. 51, 913–920 (2010).

    Article  CAS  Google Scholar 

  6. Sherriff, F. E. et al. Ubiquitinated inclusions in inclusion-body myositis patients are immunoreactive for cathepsin D but not beta-amyloid. Neurosci. Lett. 194, 37–40 (1995).

    Article  CAS  Google Scholar 

  7. Park, M. A. et al. 18F-Florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. Circ. Cardiovasc. Imaging 8, e002954 (2015).

    Article  Google Scholar 

  8. Pinal-Fernandez, I. et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann. Rheum. Dis. 76, 681–687 (2017).

    Article  Google Scholar 

  9. Tasca, G. et al. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve 52, 956–962 (2015).

    Article  Google Scholar 

  10. Lloyd, T. E. et al. Cytosolic 5′-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res. 68, 66–71 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Health Sciences, Universitat Oberta de Catalunya, Barcelona, Spain

    Iago Pinal-Fernandez

  2. Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA

    Iago Pinal-Fernandez & Andrew L. Mammen

  3. Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Iago Pinal-Fernandez & Andrew L. Mammen

Authors
  1. Iago Pinal-Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew L. Mammen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew L. Mammen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pinal-Fernandez, I., Mammen, A.L. Amyloid-PET: a new tool for diagnosing IBM?. Nat Rev Rheumatol 15, 321–322 (2019). https://doi.org/10.1038/s41584-019-0223-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-019-0223-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing